Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients

Summary

To evaluate the effect of re-administration of gefitinib to EGFR-mutated NSCLC patients who had been treated with at least one line of TKIs followed by another line of treatment (non-TKI)

Timeline

Start

2014-01

Primary completion

2017-01

Completion

2017-06

Drugs

Indications